Outcome of Board Meeting

Date: 13th August, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai-400051 Scrip Code: 540937 Symbol: MEDICO Dear Sir/Madam, Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations”) Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 13th August, 2026 has, inter alia considered and approved the following: 1. Quarterly Standalone Financial Results of the Company for the quarter ended on 30th June, 2026 along with the Limited Review Report thereon; (enclosed); 2. Re-appointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director of the Company; 3. Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Wholetime Director of the Company; 4. Increase in Remuneration payable to Mr. Harshit Mehta (DIN: 05144280) Managing Director of the Company; and 5. Notice of 32nd AGM of the Company The requisite disclosure pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure 'A'. We wish to inform you that the Board Meeting commenced today at 3:30 P.M. and concluded at 05:20 P.M. Kindly take the same on record. Thanking you, FOR MEDICO REMEDIES LIMITED HARESH MEHTA CHAIRMAN & WHOLE-TIME DIRECTOR DIN: 01080289 Encl: As above Annexure-A Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 Re-appointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director of the Company Sr. Requirement of Disclosure Details 1 Reason of change viz. appointment, : Mr. Rishit Mehta has re-appointed as Whole-Time resignation, removal, death or Director of the Company w.e.f. 18th September, 2026. otherwise 2 Date of Appointment/cessation & : w.e.f. 18th September, 2026 for the consecutive period Term of appointment of 3 Years 3 Brief Profile : Mr. Rihit Mehta is the Whole-time Director of the Company. He holds Bachelor of Engineering, Chemical from University of Mumbai and Master’s Degree of Science from the Rutgers, the State University of New Jersey. He overlooks the Production (Technical) and Quality Control department of the Company. He has around 10+ years of experience in the pharmaceutical Industry. 4 Disclosure of relationships between : Immediate relative to Mrs. Rita Mehta, Mr. Harshit directors Mehta and Mr. Haresh Mehta 5 Confirmation in compliance with Mr. Rishit Mehta is not debarred from holding the office SEBI Letter dated June 14, 2018 read of Director pursuant to any SEBI Order or Order of any along with BSE circular Number such authority. LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018 Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Wholetime Director of the Company Sr. Requirement of Disclosure Details 1 Reason of change viz. appointment, : Mr. Haresh Mehta has re-appointed as Whole-Time resignation, removal, death or Director of the Company w.e.f. 18th September, 2026. otherwise 2 Date of Appointment/cessation & : w.e.f. 18th September, 2026 for the consecutive period Term of appointment of 3 Years 3 Brief Profile : Mr. Haresh Mehta, a founding member, serves as the Chairman Whole time Director & Chief Financial Officer of the Company. He holds Bachelor’s Degree of Pharmacy from the University of Bombay and a diploma in Industrial Management from Xavier Institute of Management. He oversees the operations with regards to Financial and Legal departments of the Company. He has approximately 45+ years of experience in pharmaceutical industry. 4 Disclosure of relationships between : Immediate relative to Mrs. Rita Mehta, Mr. Harshit directors Mehta and Mr. Rishit Mehta 5 Confirmation in compliance with Mr. Haresh Mehta is not debarred from holding the SEBI Letter dated June 14, 2018 read office of Director pursuant to any SEBI Order or Order along with BSE circular Number of any such authority. LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018 Shah Shroff & Associates Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended THE BOARD OF DIRECTORS MEDICO REMEDIES LIMITED 1105/1106, 11th Floor, Hubtown Solaris Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai - 400069 Dear Sirs, Re: Limited Review Report of the Unaudited Standalone Financial Results for the quarter ended 30" June, 2026 We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") for the quarter ended 30" June 2026 together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 (‘the Regulation') as amended (the "Listing Regulations"). This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board ofD irectors at their respective meetings held on 13" August 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. ‘A703, Winsway Complex, Old Police Lane, Andheri (E), Mumbai - 400 069. Tel: +91-22 - 6127 7488 / 6697 3268 Email: shahshroff@gmail.com Continuation Sheet Shah Shroff Based on our review conducted as above, nothing has come to our attentio%h{i}gzfig&lag% believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement. Other Matters We have reviewed the financial results for quarter ended 30" June 2026. The review for the period from 1 April 2025 to 30 June 2025 was done by the previous auditor (M/s V J Shah & Co) of the Company. We have not performed any procedures for those periods, and our report is not modified in respect of those matters. For Shah Shrof [Showing first 8,000 characters — download PDF for full document]